Evergreen Advisors’s Corcept Therapeutics CORT Stock Holding History

Evergreen Advisors’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-100	Closed	-$4.03K	–	62
2026 Q1	$4.03K	Buy	+100	New	+$3.74K	﹤0.01%	137

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Evergreen Advisors's CORT Position: Q2 2026 in Review

Evergreen Advisors sold out of Corcept Therapeutics (CORT) in Q2 2026, closing a stake of 100 shares — an estimated $4.03K sold.

Evergreen Advisors first reported a position in CORT in Q1 2026 and held it in 1 quarter. The position peaked at $4.03K in Q1 2026. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Evergreen Advisors reported no remaining Corcept Therapeutics position as of Q2 2026 after selling out during the quarter.
Evergreen Advisors sold 100 Corcept Therapeutics shares in Q2 2026, an estimated $4.03K.
Evergreen Advisors first reported a position in Corcept Therapeutics in Q1 2026 and held it in 1 quarter.
Evergreen Advisors's Corcept Therapeutics position peaked at $4.03K in Q1 2026.
423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Evergreen Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.